secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2023-12-26T23:59:59+00:00
Accession:  0001104659-23-129004
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx receives FDA approval for expanded Barostim labeling; annual market opportunity increases to $2.2B
--------------------------------------------------------------------------------

- FDA approved revised Instructions For Use for Barostim incorporating long-term BeAT-HF trial data (NYHA Class III/II, EF ≤35%, NT-proBNP <1600 pg/ml).
- Clinical Summary includes 6/12/24-month data, win ratio, all-cause mortality; primary safety endpoint met, but CV death+HF hospitalization endpoint not met.
- U.S. annual market opportunity revised to $2.2B (76,000 new patients) from $1.4B (55,000), increases of ~60% and 38%.
- CEO Nadim Yared highlighted validation of long-term results and ability to share data with physicians and patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465923129004/0001104659-23-129004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465923129004/tm2333686d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-129004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer